Citigroup Maintains Buy on Kymera Therapeutics, Raises Price Target to $150

Benzinga · 2d ago
Citigroup analyst Geoff Meacham maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $150.